Scilex Holding (SCLX)

Scilex’s commercial portfolio includes ZTlido, a prescription lidocaine topical system used for relief of neuropathic pain associated with postherpetic neuralgia, a nerve pain condition that can follow shingles. The product positions the company in a market where localised pain relief and tolerability are important considerations. Scilex also markets ELYXYB, a ready-to-use oral solution of celecoxib for the acute treatment of migraine in adults, and GLOPERBA, a liquid oral formulation of colchicine indicated for the prophylaxis of painful gout flares in adults.

The company’s focus on non-opioid therapies reflects a broader healthcare need to manage pain effectively while reducing reliance on addictive medicines. Its products address different treatment settings, from topical pain relief to migraine therapy and gout flare prevention. Commercial execution depends on physician awareness, payer access, prescription demand, manufacturing reliability, and competition from branded and generic alternatives.

As a listed healthcare company, Scilex is evaluated on product sales, pipeline progress, regulatory matters, financing needs, and its ability to build a sustainable pain-management franchise. Its distinctive feature is its concentration on targeted, non-opioid options for patients with painful conditions that can significantly affect quality of life.